未登录 分享 收藏
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial Pattzi, H. M. R.; Pitale, S.; Alpizar, M.; Bennett, C.; O'Farrell, A. M.; Li, J.; Cherrington, J. M.; Guler, H. -P. 分享 收藏
The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus Garcia-Soria, G.; Gonzalez-Galvez, G.; Argoud, G. M.; Gerstman, M.; Littlejohn, T. W., III; Schwartz, S. L.; O'Farrell, A. -M.; Li, X.; Cherrington, J. M.; Bennett, C.; Guler, H. -P. 分享 收藏
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: Double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects O'Farrell, A. Marie; van Vliet, Andre; Abou Farha, Khalid; Cherrington, Julie M.; Campbell, David A.; Li, Xinqiang; Hanway, Denise; Li, Jianke; Guler, Hans-Peter 分享 收藏
FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248) Schittenhelm, M. M.; Yee, K. W. H.; Tyner, J. W.; McGreevey, L.; Haley, A. D.; Town, A.; Griffith, D. J.; Bainbridge, T.; Braziel, R. M.; O'Farrell, A. -M.; Cherrington, J. M.; Heinrich, M. C. 分享 收藏
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity Patyna, Shem; Laird, A. Douglas; Mendel, Dirk B.; O'Farrell, Anne-Marie; Liang, Chris; Guan, Huiping; Voikovsky, Tomas; Vasile, Stefan; Wang, Xueyan; Chen, Jeffrey; Grazzini, Maren; Yang, Cheng Y.; Haznedar, Joshua O.; Sukbuntherng, Juthamas; Zhong, Wei-Zhu; Cherrington, Julie M.; Hu-Lowe, Dana 分享 收藏
分享 收藏
分享 收藏
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma Zangari, M; Anaissie, E; Stopeck, A; Morimoto, A; Tan, N; Lancet, J; Cooper, M; Hannah, A; Garcia-Manero, G; Faderl, S; Kantarjian, H; Cherrington, J; Albitar, M; Giles, FJ 分享 收藏
分享 收藏
Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases SU5416-一种小分子，血管内皮生长因子酪氨酸激酶受体抑制剂-在难治性骨髓增生性疾病患者中的II期研究 Giles, FJ; Cooper, MA; Silverman, L; Karp, JE; Lancet, JE; Zangari, M; Shami, PJ; Khan, KD; Hannah, AL; Cherrington, JM; Thomas, DA; Garcia-Manero, G; Albitar, M; Kantarjian, HM; Stopeck, AT 分享 收藏
分享 收藏
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model Murray, LJ; Abrams, TJ; Long, KR; Ngai, TJ; Olson, LM; Hong, WR; Keast, PK; Brassard, JA; O'Farrell, AM; Cherrington, JM; Pryer, NK 分享 收藏
分享 收藏
SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice Laird, AD; Christensen, JG; Li, GM; Carver, J; Smith, K; Xin, XH; Moss, KG; Louie, SG; Mendel, DB; Cherrington, JM 分享 收藏
分享 收藏
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA Van Rompay, KKA; Miller, MD; Marthas, ML; Margot, NA; Dailey, PJ; Canfield, DR; Tarara, RP; Cherrington, JM; Aguirre, NL; Bischofberger, N; Pedersen, NC 分享 收藏
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques Van Rompay, KKA; Dailey, PJ; Tarara, RP; Canfield, DR; Aguirre, NL; Cherrington, JM; Lamy, PD; Bischofberger, N; Pedersen, NC; Marthas, ML 分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
